Rigel Pharmaceuticals (RIGL) Equity Average (2011 - 2026)
Rigel Pharmaceuticals' quarterly Equity Average came in at $395.7 million in Q1 2026, up 3521.03% year-on-year from $10.9 million in Q1 2025, and up 55.45% quarter-over-quarter from $254.5 million in Q4 2025.
Rigel Pharmaceuticals has reported Equity Average for 16 years, with the latest figure at $395.7 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 3521.03% year-over-year to $395.7 million; the trailing twelve-month figure through Mar 2026 stood at $395.7 million (up 3521.03% YoY), and the FY2025 full-year result was $197.4 million, up 1656.9% from the prior year.
- Equity Average for Q1 2026 stood at $395.7 million, up from $254.5 million in the prior quarter.
- The five-year high for Equity Average was $395.7 million in Q1 2026, with the low at -$30.8 million in Q2 2024.
- Average Equity Average over 5 years is $35.8 million, with a median of -$11.8 million recorded in 2022.
- Year-over-year, Equity Average sank 1778.05% in 2023 and surged 4586.16% in 2025.
- Tracing RIGL's Equity Average over 5 years: stood at -$16.7 million in 2022, then sank by 80.8% to -$30.2 million in 2023, then soared by 81.24% to -$5.7 million in 2024, then surged by 4586.16% to $254.5 million in 2025, then surged by 55.45% to $395.7 million in 2026.
- The last three Equity Average figures came in at $395.7 million (Q1 2026), $254.5 million (Q4 2025), and $99.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 395.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 395.69 Mn |
| Dec 31, 2025 | 254.54 Mn |
| Sep 30, 2025 | 99.77 Mn |
| Jun 30, 2025 | 50.25 Mn |
| Mar 31, 2025 | 10.93 Mn |
| Dec 31, 2024 | -5.67 Mn |
| Sep 30, 2024 | -22.28 Mn |
| Jun 30, 2024 | -30.79 Mn |
| Mar 31, 2024 | -30.16 Mn |
| Dec 31, 2023 | -30.24 Mn |
| Sep 30, 2023 | -29.97 Mn |
| Jun 30, 2023 | -26.19 Mn |
| Mar 31, 2023 | -18.94 Mn |
| Dec 31, 2022 | -16.73 Mn |
| Sep 30, 2022 | -11.76 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Mar 31, 2022 | 18.59 Mn |
| Dec 31, 2021 | 40.02 Mn |
| Sep 30, 2021 | 58.89 Mn |
| Jun 30, 2021 | 73.20 Mn |
| Mar 31, 2021 | 56.16 Mn |
| Dec 31, 2020 | 42.49 Mn |
| Sep 30, 2020 | 57.08 Mn |
| Jun 30, 2020 | 70.85 Mn |
| Mar 31, 2020 | 66.16 Mn |
| Dec 31, 2019 | 61.36 Mn |
| Sep 30, 2019 | 73.60 Mn |
| Jun 30, 2019 | 86.80 Mn |
| Mar 31, 2019 | 102.60 Mn |
| Dec 31, 2018 | 106.68 Mn |
| Sep 30, 2018 | 113.52 Mn |
| Jun 30, 2018 | 101.69 Mn |
| Mar 31, 2018 | 90.23 Mn |
| Dec 31, 2017 | 78.41 Mn |
| Sep 30, 2017 | 62.89 Mn |
| Jun 30, 2017 | 76.84 Mn |
| Mar 31, 2017 | 69.55 Mn |
| Dec 31, 2016 | 60.49 Mn |
| Sep 30, 2016 | 69.83 Mn |
| Jun 30, 2016 | 74.59 Mn |
| Mar 31, 2016 | 83.42 Mn |
| Dec 31, 2015 | 93.89 Mn |
| Sep 30, 2015 | 98.78 Mn |
| Jun 30, 2015 | 106.65 Mn |
| Mar 31, 2015 | 120.20 Mn |
| Dec 31, 2014 | 137.55 Mn |
| Sep 30, 2014 | 156.29 Mn |
| Jun 30, 2014 | 177.03 Mn |
| Mar 31, 2014 | 198.29 Mn |
| Dec 31, 2013 | 215.83 Mn |
| Sep 30, 2013 | 234.23 Mn |
| Jun 30, 2013 | 255.18 Mn |
| Mar 31, 2013 | 277.20 Mn |
| Dec 31, 2012 | 231.95 Mn |
| Sep 30, 2012 | 185.28 Mn |
| Jun 30, 2012 | 206.17 Mn |
| Mar 31, 2012 | 226.36 Mn |
| Dec 31, 2011 | 247.06 Mn |
| Sep 30, 2011 | 265.32 Mn |